Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy

  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Santos, José Ramón|||0000-0002-0886-7114
  • Peña, Ruth
  • Jiménez Moyano, Esther
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Paredes, Roger|||0000-0002-6553-691X
  • Prado, Julia G.|||0000-0002-5439-4645
Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene. From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir monotherapy, we retrospectively identified nine patients with VF. We sequenced the HIV-1 Gag-protease region and generated clonal virus from plasma samples. We characterized phenotypically clonal variants in terms of replicative capacity and susceptibility to PIs. Also, we used VESPA to identify signature mutations and 3D molecular modelling information to detect conformational changes in the Gag region. All subjects analysed harboured Gag-associated polymorphisms in the absence of resistance mutations in the protease gene. Most Gag changes occurred outside Gag cleavage sites. VESPA analyses identified K95R and R286K (P < 0.01) as signature mutations in Gag present at VF. In one out of four patients with clonal analysis available, we identified clonal variants with high replicative capacity and 8- to 13-fold reduction in darunavir susceptibility. These clonal variants harboured K95R, R286K and additional mutations in Gag. Low susceptibility to darunavir was dependent on the Gag sequence context. All other clonal variants analysed preserved drug susceptibility and virus replicative capacity. Gag mutations may reduce darunavir susceptibility in the absence of protease mutations while preserving viral fitness. This effect is Gag-sequence context dependent and may occur during boosted PI failure.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells

  • Astorga-Gamaza, Antonio|||0000-0002-1276-5276
  • Vitali, Michele|||0000-0001-8618-8988
  • Borrajo, Mireya L.
  • Suárez-López, Rosa
  • Jaime, Carlos|||0000-0002-9690-9053
  • Bastús, Neus G.|||0000-0002-3144-7986
  • Serra-Peinado, Carla|||0000-0003-1413-3990
  • Luque-Ballesteros, Laura|||0000-0001-9515-5889
  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Prado, Julia G.|||0000-0002-5439-4645
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
  • Pumarola, Felix|||0000-0002-7914-1695
  • Pellicer, Marc
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
  • Puntes, Víctor|||0000-0001-8996-9499
  • Buzón, Maria José|||0000-0003-4427-9413
HIV represents a persistent infection which negatively alters the immune system. New tools to reinvigorate different immune cell populations to impact HIV are needed. Herein, a novel nanotool for the specific enhancement of the natural killer (NK) immune response towards HIV-infected T-cells has been developed. Bispecific Au nanoparticles (BiAb-AuNPs), dually conjugated with IgG anti-HIVgp120 and IgG anti-human CD16 antibodies, were generated by a new controlled, linker-free and cooperative conjugation method promoting the ordered distribution and segregation of antibodies in domains. The cooperatively-adsorbed antibodies fully retained the capabilities to recognize their cognate antigen and were able to significantly enhance cell-to-cell contact between HIV-expressing cells and NK cells. As a consequence, the BiAb-AuNPs triggered a potent cytotoxic response against HIV-infected cells in blood and human tonsil explants. Remarkably, the BiAb-AuNPs were able to significantly reduce latent HIV infection after viral reactivation in a primary cell model of HIV latency. This novel molecularly-targeted strategy using a bispecific nanotool to enhance the immune system represents a new approximation with potential applications beyond HIV.